← Browse by Condition
Medical Condition
pancreatic ductal adenocarcinoma
Total Trials
9
Recruiting Now
9
Trial Phases
Phase 1, Phase 2, Phase 2, Phase 3, Phase 1
ClinicalMetric tracks all active clinical trials for pancreatic ductal adenocarcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.
Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.
Frequently Asked Questions — pancreatic ductal adenocarcinoma Clinical Trials
How many clinical trials are currently recruiting for pancreatic ductal adenocarcinoma?
ClinicalMetric currently tracks 9 actively recruiting clinical trials for pancreatic ductal adenocarcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 9. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for pancreatic ductal adenocarcinoma?
pancreatic ductal adenocarcinoma research spans Phase 1 (4 trials), Phase 2 (6 trials), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a pancreatic ductal adenocarcinoma clinical trial?
Eligibility criteria for pancreatic ductal adenocarcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 4
Phase 2 6
Phase 3 2
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT07432633 Phase 1, Phase 2
Recruiting
Enrollment
71 pts
Location
United States
Sponsor
Blue Earth Diagnostics
NCT06782412 Phase 2, Phase 3
Recruiting
Enrollment
109 pts
Location
Belgium
Sponsor
KU Leuven
NCT06562192 Phase 1
Recruiting
Enrollment
162 pts
Location
United States, Belgi...
Sponsor
Novartis Pharmaceuticals
NCT06015724 Phase 2
Recruiting
Enrollment
54 pts
Location
United States
Sponsor
Georgetown University
NCT05254171 Phase 2, Phase 3
Recruiting
Enrollment
600 pts
Location
United States, Austr...
Sponsor
Panbela Therapeutics, Inc.
NCT04851119 Phase 1, Phase 2
Recruiting
Enrollment
147 pts
Location
United States
Sponsor
Children's Oncology Group
NCT06467565 Phase 2
Recruiting
Enrollment
20 pts
Location
China
Sponsor
The First Affiliated Hospital ...
NCT06999187 Phase 1
Recruiting
Enrollment
96 pts
Location
United States
Sponsor
Dren Bio
NCT06600906
Recruiting
Enrollment
70 pts
Location
United States
Sponsor
University of California, San ...
Related Conditions
gastric cancer (3) colorectal cancer (2) non small cell lung cancer (2) triple negative breast cancer (2) epithelial ovarian cancer (1) invasive lobular breast carcinoma (1) oesophageal cancer (1) fap (1) oncology (1) oncologic disorders (1) hr her2 ductal and lobular breast cancer (1) refractory non small cell lung cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology